Sanofi-Aventis will still proceed with hostile offer

first_img Read This NextRicky Schroder Calls Foo Fighters’ Dave Grohl ‘Ignorant Punk’ forThe WrapCNN’s Brian Stelter Draws Criticism for Asking Jen Psaki: ‘What Does theThe WrapDid Donald Trump Wear His Pants Backwards? Kriss Kross Memes Have AlreadyThe WrapHarvey Weinstein to Be Extradited to California to Face Sexual AssaultThe Wrap’Sex and the City’ Sequel Series at HBO Max Adds 4 More ReturningThe WrapPink Floyd’s Roger Waters Denies Zuckerberg’s Request to Use Song in Ad:The Wrap’The View’: Meghan McCain Calls VP Kamala Harris a ‘Moron’ for BorderThe WrapNewsmax Rejected Matt Gaetz When Congressman ‘Reached Out’ for a JobThe Wrap2 HFPA Members Resign Citing a Culture of ‘Corruption and Verbal Abuse’The Wrap whatsapp by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeMisterStoryWoman Files For Divorce After Seeing This Photo – Can You See Why?MisterStoryTotal PastThe Ingenious Reason There Are No Mosquitoes At Disney WorldTotal PastMoneyPailShe Was A Star, Now She Works In ScottsdaleMoneyPailSerendipity TimesInside Coco Chanel’s Eerily Abandoned Mansion Frozen In TimeSerendipity TimesBrake For ItThe Most Worthless Cars Ever MadeBrake For ItBetterBe20 Stunning Female AthletesBetterBemoneycougar.comThis Proves The Osmonds Weren’t So Innocentmoneycougar.comMagellan TimesThis Is Why The Roy Rogers Museum Has Been Closed For GoodMagellan TimesElite HeraldExperts Discover Girl Born From Two Different SpeciesElite Herald Show Comments ▼ Sanofi-Aventis’ position remains unchanged regarding a $18.5bn (£11.6bn) hostile offer for Genzyme, Sanofi chief executive Chris Viehbacher said yesterday.“Our position was made very clear at the time we made the offer and nothing’s changed,” said Viehbacher yesterday when asked if anything had altered in his position since Sanofi denied floating the idea of an $80 per share offer for the US biotech.On 4 October Sanofi-Aventis went directly to Genzyme shareholders with a cash offer of $69 a share, after Genzyme refused to open its books to friendly merger talks dismissing Sanofi’s initial offer as too low.Three days later, Genzyme’s chief executive Henri Termeer said in a regulatory filing that Viehbacher proposed a deal price range of $69 to $80 per share at a joint chief executives meeting in late September, two weeks before it went hostile. KCS-content Thursday 14 October 2010 9:37 pmcenter_img Sanofi-Aventis will still proceed with hostile offer Share Tags: NULL whatsapplast_img

Leave a Reply

Your email address will not be published. Required fields are marked *